Clinart Brings Clinerion into MENA Region
Clinart will collaborate with Clinerion to expand its international network of healthcare institution partners in the Middle East and North Africa (MENA) region. Clinart will also offer Clinerion’s services to advance academic and sponsored research in MENA.
Clinart has a position as an innovative regional contract research organization offering a full-service end-to-end solution and access in the MENA region. Clinart will support Clinerion by linking sites and hospitals to the global network on Clinerion’s Patient Network Explorer (PNEx) platform. This will help hospitals in the region be more visible and accessible for global trial sponsors and attract more studies to the region. Clinart will also offer services derived from PNEx for the running of local real-world evidence studies and academic research.
The partnership supports Clinart’s vision to support patients and healthcare providers by making the region more visible to trial sponsors, attracting more international studies to the region, enabling capable local organizations to run real-world evidence projects, and facilitating local academic research across the region.
The collaboration will initially focus on the Gulf countries of the United Arab Emirates and Saudi Arabia. This will expand later to other countries in the region.
“We are very excited about the opportunity to partner with Clinerion in the MENA region,” says Alaa Assem, President & CEO of Clinart. “We believe that the region can benefit from this partnership through the improvement of visibility of the region on a global level. By providing better access to Real World Evidence data and analytics from the region, we can generate a better understanding of disease prevalence and treatment patterns in geographies which are currently underrepresented. We are strongly positioned to support Clinerion with this initiative and also to support the sites with establishing the required infrastructure and resources needed to successfully deliver.”
“Clinerion is thrilled to have a partner who can support us in our efforts to improve patient outcomes in the MENA region,” says Ian Rentsch, CEO of Clinerion. “Clinart has an excellent reputation and a network capable of making things happen.”
For more information go to www.clinerion.com
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
Final ENLIVEN Trial Results Confirm Long-Term Benefit of Turalio in Tenosynovial Giant Cell Tumor
July 9th 2025In final data from the Phase III ENLIVEN study, Turalio (pexidartinib) demonstrated durable tumor responses and a consistent safety profile in patients with symptomatic TGCT not amenable to surgery.
